Article Type
Changed
Fri, 01/18/2019 - 15:03
Display Headline
IHC: Acupuncture deflates migraine

VALENCIA, SPAIN – Acupuncture is as effective as standard pharmacotherapy for migraine prophylaxis, according to a randomized, clinical trial. Forty-four percent of patients in the acupuncture group were deemed treatment responders based upon at least a 50% reduction in headache days per month at 4 months of follow-up, compared with baseline, Dr. Giulia Giannini reported at the International Headache Congress.

The responder rate in the prophylactic pharmacotherapy group was similar at 38%. However, it must be noted that half of the migraineurs assigned to the medication group dropped out of the study for various reasons – No. 1 being treatment side effects – and in this study the responder rate was based upon patients who made it to the 4-month mark, noted Dr. Giannini of the University of Bologna (Italy).

©edwardolive/Thinkstock.com

The study included 85 patients, none of whom had been on prophylactic medication during the previous 3 months. They were randomized to a series of 12 acupuncture sessions or to whatever conventional prophylactic drug the physician and patient agreed was most appropriate.

Eight of 42 patients in the acupuncture group and 21 of 43 controls discontinued the study.

Among the study completers in the acupuncture group, migraine frequency dropped from 9.26 headache days per month at baseline to 6 days per month at 4 months. The group on prophylactic pharmacotherapy improved from 7.95 to 6.24 headache days per month.

These results are consistent with the findings of several published clinical trials comparing acupuncture with prophylactic antimigraine drugs, including one in which acupuncture proved more effective than valproic acid (Minerva Anestesiol. 2013;79:634-42). The published data prompted a Cochrane systematic review which concluded that acupuncture is at least as effective as prophylactic drug therapy, has fewer adverse effects, and should be considered a legitimate treatment option (Cochrane Database Syst. Rev. 2009 [doi:10.1002/14651858.CD001218.pub2]). Dr. Giannini noted at the meeting sponsored by the International Headache Society and the American Headache Society.

No serious adverse events occurred in either study arm.

The study was funded by the Emilia-Romagna (Italy) Department of Health. Dr. Giannini reported having no financial conflicts.

bjancin@frontlinemedcom.com

References

Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
acupuncture, migraine prophylaxis
Sections
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

VALENCIA, SPAIN – Acupuncture is as effective as standard pharmacotherapy for migraine prophylaxis, according to a randomized, clinical trial. Forty-four percent of patients in the acupuncture group were deemed treatment responders based upon at least a 50% reduction in headache days per month at 4 months of follow-up, compared with baseline, Dr. Giulia Giannini reported at the International Headache Congress.

The responder rate in the prophylactic pharmacotherapy group was similar at 38%. However, it must be noted that half of the migraineurs assigned to the medication group dropped out of the study for various reasons – No. 1 being treatment side effects – and in this study the responder rate was based upon patients who made it to the 4-month mark, noted Dr. Giannini of the University of Bologna (Italy).

©edwardolive/Thinkstock.com

The study included 85 patients, none of whom had been on prophylactic medication during the previous 3 months. They were randomized to a series of 12 acupuncture sessions or to whatever conventional prophylactic drug the physician and patient agreed was most appropriate.

Eight of 42 patients in the acupuncture group and 21 of 43 controls discontinued the study.

Among the study completers in the acupuncture group, migraine frequency dropped from 9.26 headache days per month at baseline to 6 days per month at 4 months. The group on prophylactic pharmacotherapy improved from 7.95 to 6.24 headache days per month.

These results are consistent with the findings of several published clinical trials comparing acupuncture with prophylactic antimigraine drugs, including one in which acupuncture proved more effective than valproic acid (Minerva Anestesiol. 2013;79:634-42). The published data prompted a Cochrane systematic review which concluded that acupuncture is at least as effective as prophylactic drug therapy, has fewer adverse effects, and should be considered a legitimate treatment option (Cochrane Database Syst. Rev. 2009 [doi:10.1002/14651858.CD001218.pub2]). Dr. Giannini noted at the meeting sponsored by the International Headache Society and the American Headache Society.

No serious adverse events occurred in either study arm.

The study was funded by the Emilia-Romagna (Italy) Department of Health. Dr. Giannini reported having no financial conflicts.

bjancin@frontlinemedcom.com

VALENCIA, SPAIN – Acupuncture is as effective as standard pharmacotherapy for migraine prophylaxis, according to a randomized, clinical trial. Forty-four percent of patients in the acupuncture group were deemed treatment responders based upon at least a 50% reduction in headache days per month at 4 months of follow-up, compared with baseline, Dr. Giulia Giannini reported at the International Headache Congress.

The responder rate in the prophylactic pharmacotherapy group was similar at 38%. However, it must be noted that half of the migraineurs assigned to the medication group dropped out of the study for various reasons – No. 1 being treatment side effects – and in this study the responder rate was based upon patients who made it to the 4-month mark, noted Dr. Giannini of the University of Bologna (Italy).

©edwardolive/Thinkstock.com

The study included 85 patients, none of whom had been on prophylactic medication during the previous 3 months. They were randomized to a series of 12 acupuncture sessions or to whatever conventional prophylactic drug the physician and patient agreed was most appropriate.

Eight of 42 patients in the acupuncture group and 21 of 43 controls discontinued the study.

Among the study completers in the acupuncture group, migraine frequency dropped from 9.26 headache days per month at baseline to 6 days per month at 4 months. The group on prophylactic pharmacotherapy improved from 7.95 to 6.24 headache days per month.

These results are consistent with the findings of several published clinical trials comparing acupuncture with prophylactic antimigraine drugs, including one in which acupuncture proved more effective than valproic acid (Minerva Anestesiol. 2013;79:634-42). The published data prompted a Cochrane systematic review which concluded that acupuncture is at least as effective as prophylactic drug therapy, has fewer adverse effects, and should be considered a legitimate treatment option (Cochrane Database Syst. Rev. 2009 [doi:10.1002/14651858.CD001218.pub2]). Dr. Giannini noted at the meeting sponsored by the International Headache Society and the American Headache Society.

No serious adverse events occurred in either study arm.

The study was funded by the Emilia-Romagna (Italy) Department of Health. Dr. Giannini reported having no financial conflicts.

bjancin@frontlinemedcom.com

References

References

Publications
Publications
Topics
Article Type
Display Headline
IHC: Acupuncture deflates migraine
Display Headline
IHC: Acupuncture deflates migraine
Legacy Keywords
acupuncture, migraine prophylaxis
Legacy Keywords
acupuncture, migraine prophylaxis
Sections
Article Source

AT IHC 2015

PURLs Copyright

Inside the Article

Vitals

Key clinical point: Acupuncture is at least as effective for migraine prophylaxis as standard preventive medications.

Major finding: Forty-four percent of migraine patients who completed 12 sessions of acupuncture had at least a 50% reduction in headache days per month at 4 months of follow-up, similar to the 38% rate in patients randomized to prophylactic medication.

Data source: This was a prospective, unblinded, randomized trial involving 85 migraineurs.

Disclosures: The study was funded by the Emilia-Romagna (Italy) Department of Health. The presenter reported having no financial conflicts.